The pathophysiological consequences of somatostatin receptor internalization and resistance

Endocrine Reviews

Volumn 24, Issue 1, 2003, Pages 28-47

  Hofland, Leo J ^a   Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTIINFECTIVE AGENT; BIM 23197; BIM 23244; BIM 23268; OCTREOTIDE; PASIREOTIDE; RADIOISOTOPE; RECEPTOR SUBTYPE; SEGLITIDE; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

DRUG EFFICACY; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

ANIMALS; DRUG RESISTANCE; GENE EXPRESSION; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TACHYPHYLAXIS;

EID: 0037323565     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2000-0001     Document Type: Review

References (202)

1. Guillemin R, Gerich JE 1976 Somatostatin: physiological and clinical significance. Annu Rev Med 27:379-388
2. Lamberts SW, Krenning EP, Reubi JC 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482
3. Schally AV 1988 Oncological applications of somatostatin analogues [published erratum appears in Cancer Res 1989 Mar 15; 49(6):1618]. Cancer Res 48:6977-6985
4. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A, Taylor JE, Reisine T 1995 Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16:86-88
5. Hoyer D, Lubbert H, Bruns C 1994 Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 350:441-453
6. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H 1994 Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 733:138-146
7. Reisine T, Bell GI 1995 Molecular biology of somatostatin receptors. Endocr Rev 16:427-442
8. Patel YC 1997 Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 20:348-367
9. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
10. Hofland LJ, Visser-Wisselaar HA, Lamberts SW 1995 Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem Pharmacol 50:287-297
11. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254
12. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW 1989 Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242-244
13. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, Visser TJ, Reÿs AEM, Hofland LJ, Keper JW, Lamberts SWJ 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
14. Reichlin S 1983 Somatostatin. N Engl J Med 309:1495-1501
15. Epelbaum J 1986 Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 27:63-100
16. Sevarino KA, Felix R, Banks CM, Low MJ, Montminy MR, Mandel G, Goodman RH 1987 Cell-specific processing of preprosomatostatin in cultured neuroendocrine cells. J Biol Chem 262:4987-4993
17. Vanetti M, Kouba M, Wang X, Vogt G, Hollt V 1992 Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett 311:290-294
18. Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB 1993 Multiple gene transcripts of the somatostatin receptor SSTR2:tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 192:288-294
19. Dournaud P, Boudin H, Schonbrunn A, Tannenbaum GS, Beaudet A 1998 Interrelationships between somatostatin sst2A receptors and somatostatin-containing axons in rat brain: evidence for regulation of cell surface receptors by endogenous somatostatin. J Neurosci 18:1056-1071
20. Panetta R, Patel YC 1995 Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333-342
21. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J 1998 Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 83:3746-3749
22. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC 1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48:77-85
23. Reubi JC, Krenning E, Lamberts SW, Kvols L 1992 In vitro detection of somatostatin receptors in human tumors. Metabolism 41:104-110
24. Reubi JC, Laissue J, Krenning E, Lamberts SW 1992 Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43:27-35
25. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC 1994 Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 733:122-137
26. Reubi JC, Schaer JC, Laissue JA, Waser B 1996 Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45:39-41
27. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S 1995 Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80:2974-2979
28. Reubi JC, Schaer JC, Waser B, Mengod G 1994 Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455-3459
29. Reubi JC, Waser B, Schaer JC, Markwalder R 1995 Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 80:2806-2814
30. Greenman Y, Melmed S 1994 Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729
31. Greenman Y, Melmed S 1994 Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398-403
32. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321-1325
33. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D, Plouin P F 1995 Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 80:1837-1844
34. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A 1995 Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386-1392
35. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A 1998 Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233-245
36. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A, Lamberts SW 1999 Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 84:775-780
37. Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C, Hollt V 1998 Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 4:2047-2052
38. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M 1999 Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5:3483-3487
39. Reubi JC, Horisberger U, Laissue J 1994 High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 56:681-688
40. Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SW, Gebbers JO, Gersbach P, Laissue JA 1993 In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 82:2143-2151
41. Reubi JC, Waser B, Schmassmann A, Laissue JA 1999 Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastrointestinal adenocarcinoma samples: where are they really located? Int J Cancer 81:376-386
42. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB 1995 The somatostatin receptor family. Life Sci 57: 1249-1265
43. Beaudet A, Nouel D, Stroh T, Vandenbulcke F, Dal-Farra C, Vincent JP 1998 Fluorescent ligands for studying neuropeptide receptors by confocal microscopy. Braz J Med Biol Res 31:1479-1489
44. Roth A, Kreienkamp HJ, Nehring RB, Roosterman D, Meyerhof W, Richter D 1997 Endocytosis of the rat somatostatin receptors: subtype discrimination, ligand specificity, and delineation of carboxy-terminal positive and negative sequence motifs. DNA Cell Biol 16:111-119
45. Csaba Z, Dournaud P 2001 Cellular biology of somatostatin receptors. Neuropeptides 35:1-23
46. Schonbrunn A 1999 Somatostatin receptors present knowledge and future directions. Ann Oncol 10:S17-S21
47. Koenig JA, Edwardson JM 1997 Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18:276-287
48. Hausdorff WP, Caron MG, Lefkowitz RJ 1990 Turning off the signal: desensitization of β-adrenergic receptor function [published erratum appears in FASEB J 1990 Sep;4(12):3049]. FASEB J 4:2881-2889
49. Ferguson SS, Barak LS, Zhang J, Caron MG 1996 G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 74:1095-1110
50. Yu SS, Lefkowitz RJ, Hausdorff WP 1993 β-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J Biol Chem 268:337-341
51. Roettger BF, Rentsch RU, Pinon D, Holicky E, Hadac E, Larkin JM, Miller LJ 1995 Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol 128:1029-1041
52. Brown MS, Goldstein JL 1986 A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47
53. Steinman RM, Mellman IS, Muller WA, Cohn ZA 1983 Endocytosis and the recycling of plasma membrane. J Cell Biol 96:1-27
54. Hukovic N, Panetta R, Kumar U, Patel YC 1996 Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 137:4046-4049
55. Nouel D, Gaudriault G, Houle M, Reisine T, Vincent JP, Mazella J, Beaudet A 1997 Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138:296-306
56. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC 2000 Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869
57. Hukovic N, Rocheville M, Kumar U, Sasi R, Khare S, Patel YC 1999 Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. J Biol Chem 274:24550-24558
58. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Hollt V, Schulz S 2001 Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276:14027-14036
59. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S 2002 Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277:19762-19772
60. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288: 154-157
61. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, Ensing GJ, Lamberts SW, Krenning EP 1995 Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 36:623-627
62. Szegedi Z, Takacs J, Szende B, Vadasz Z, Horvath A, Gulyas E, Toth G, Petak I, Bocsi J, Keri G 1999 A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells. Endocrine 10:25-34
63. Andersson P, Forssell-Aronsson E, Johanson V, Wangberg B, Nilsson O, Fjalling M, Ahlman H 1996 Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med 37:2002-2006
64. Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A 2000 Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med 41:1514-1518
65. 125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 136:3698-3706
66. Koenig JA, Edwardson JM, Humphrey PP 1997 Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization. Br J Pharmacol 120:52-59
67. de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE, Macke HR, Krenning EP 1998 Comparison of (I11)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58:437-441
68. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A 1997 Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272: 13869-13876
69. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K 1998 Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 58:2375-2378
70. Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, Raggi CC, Serio M, Maggi M 1997 Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 3:2385-2391
71. Ferone D, van Hagen MP, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E, Schonbrunn A, Colao A, Lamberts SW, Hofland LJ 2000 Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 85:1719-1726
72. Kolby L, Wangberg B, Ahlman H, Tisell LE, Fjalling M, Forssell-Aronsson E, Nilsson O 1998 Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 22:679-683
73. Kristiansen MT, Rasmussen LM, Olsen N, Asa SL, Jorgensen JO 2002 Ectopic ACTH syndrome: discrepancy between somatostatin receptor status in vivo and ex vivo, and between immunostaining and gene transcription for POMC and CRH. Horm Res 57:200-204
74. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99:789-798
75. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392
76. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C 1998 The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-D-Phe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 25: 668-674
77. 125I-Tyr3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Physicians 111:63-69
78. De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ, Macke HR, Krenning EP 1998 Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 19:283-288
79. Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP 1999 Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40:762-767
80. Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PPA 1998 Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J 336:291-298
81. Roth A, Kreienkamp HJ, Meyerhof W, Richter D 1997 Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J Biol Chem 272:23769-23774
82. Duncan JR, Stephenson MT, Wu HP, Anderson CJ 1997 Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 57:659-671
83. Bass LA, Lanahan MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, Anderson CJ 1998 Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide. Bioconjug Chem 9:192-200
84. Akizawa H, Arano Y, Uezono T, Ono M, Fujioka Y, Uehara T, Yokoyama A, Akaji K, Kiso Y, Koizumi M, Saji H 1998 Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. Bioconjug Chem 9:662-670
85. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA 2000 Progressive nuclear translocation of somatostatin analogs. J Nucl Med 41:1256-1263
86. Kooij PPM, Kwekkeboom DJ, Breeman WAP, Reijs AEM, Bakker WH, Lamberts SWJ, Visser TJ, Krenning EP 1994 The effects of specific activity on tissue distribution of [In-111-DTPA-D-Phe1]octreotide in humans. J Nucl Med 35:226P
87. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Macke HR, Krenning EP 1999 Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 26:693-698
88. Breeman WA, Hofland LJ, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW 1994 A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med 21:328-335
89. Breeman WAP, van Hagen PM, Kwekkeboom DJ, Visser TJ, Krenning EP 1998 Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide. Eur J Nucl Med 25:182-186
90. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I 1999 DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 140:5136-5148
91. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR 2000 Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-282
92. Ronga G, Salerno G, Procaccini E, Mauro L, Annovazzi A, Barone R, Mellozzi M, Tamburrano G, Signore A 1995 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible downregulation of somatostatin receptors. Q J Nucl Med 39:134-136
93. Krassas GE, Doumas A, Kaltsas T, Halkias A, Pontikides N 1999 Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid 9:47-52
94. Schillaci O, Annibale B, Scopinaro F, delle Fave G, Colella AC 1997 Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide. J Nucl Med 38:886-887
95. Lamberts SW, Hofland LJ, van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, Krenning EP 1990 Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 71:566-574
96. Dorr U, Wurm K, Horing E, Guzman G, Rath U, Bihl H 1993 Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Horm Metab Res Suppl 27:36-43
97. Zamora PO, Gulhke S, Bender H, Diekmann D, Rhodes BA, Biersack HJ, Knapp Jr FF 1996 Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 65:214-220
98. Zamora PO, Bender H, Gulhke S, Marek MJ, Knapp Jr FF, Rhodes BA, Biersack HJ 1997 Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res 17:1803-1808
99. Stolz B, Smith-Jones P, Albert R, Tolcsvai L, Briner U, Ruser G, Macke H, Weckbecker G, Bruns C 1996 Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 57:17-21
100. Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH 1999 Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 81:767-771
101. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP 2001 [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92:628-633
102. Krenning EP, de Jong M, Jamar F, Valkema R, Kwekkeboom DJ, Kvols LK, Smith C, Pauwels S 2002 Somatostatin receptor-targeted radiotherapy of tumors: preclinical and clinical findings. In: Lamberts SWJ, Dogliotti L, eds. The expanding role of octreotide I: advances in oncology. Bristol, UK: Bioscientifica Ltd., 211-223
103. de Jong M, Krenning E 2002 New advances in peptide receptor radionuclide therapy. J Nucl Med 43:617-620
104. Gallardo D, Drazan KE, McBride WH 1996 Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56:4891-4893
105. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K, Takahashi T 1996 Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 67:101-105
106. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dorken B 1996 Induction of the death-promoting gene bax-α sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67:138-141
107. Sharma K, Srikant CB 1998 Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 76:259-266
108. Sharma K, Patel YC, Srikant CB 1996 Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688-1696
109. Sharma K, Patel YC, Srikant CB 1999 C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 13:82-90
110. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L 1999 sst2 Somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 274:15186-15193
111. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R 1999 Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10:S23-S29
112. Fjalling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, Wangberg B, Nilsson O, Berg G, Michanek A, Lindstedt G, Ahlman H 1996 Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 37:1519-1521
113. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP 2002 Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32:110-122
114. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB 1998 In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 4:94-102
115. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR 1998 Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417-418
116. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J 1999 Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26:1439-1447
117. Paganelli G, Zoboli S, Cremonesi M, Macke HR, Chinol M 1999 Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm 14:477-483
118. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F 2001 Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 28:426-434
119. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J 2001 The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12:941-945
120. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J 2002 Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610-616
121. Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederle B, Herold C, Virgolini I 1998 Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 39:2090-2094
122. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP 2001 [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319-1325
123. Schally AV, Nagy A 1999 Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141:1-14
124. Radulovic S, Nagy A, Szoke B, Schally AV 1992 Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett 62:263-271
125. Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovacs M, Koppan M, Szepeshazi K, Kahan Z 1998 Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 95:1794-1799
126. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K 1999 Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 59:1947-1953
127. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G 2000 Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60:2996-3001
128. Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, Halmos G 2001 Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer 92:1168-1176
129. Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G 2000 Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 6:709-717
130. Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G 2001 A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer 37:620-628
131. Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A 2001 Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin Cancer Res 7:2854-2861
132. Kahan Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G 1999 Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 82:592-598
133. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G 1998 Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 58:4132-4137
134. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan AL, Frohman LA, Melmed S 1992 Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117:711-718
135. Lamberts SW 1988 The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 9:417-436
136. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM 1998 Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 48:311-316
137. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J 1997 Sandostatin LAR in acromegalic patients: longterm treatment. J Clin Endocrinol Metab 82:23-28
138. Gillis JC, Noble S, Goa KL 1997 Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53:681-699
139. Caron P, Morange-Ramos I, Cogne M, Jaquet P 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18-22
140. Haraguchi K, Ohtaka M, Takazawa K, Endo T, Onaya T 1995 Desensitization to somatostatin analogue (octreotide) observed in a patient with acromegaly. Endocr J 42:295-300
141. Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG 2002 Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 146:295-302
142. Chanson P, Weintraub BD, Harris AG 1993 Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119:236-240
143. de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, Croughs RJ 1992 Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 75:1310-1317
144. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD 1996 Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610-638
145. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663-666
146. Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O'Connell MJ, Hahn RG 1987 Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Arm Intern Med 107: 162-168
147. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG, Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17:1111
148. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Bernades P, Rougier P 1996 Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39:279-283
149. Moertel CG 1987 Karnofsky memorial lecture. An odyssey in the land of
150. Lamberts SW, Pieters GF, Metselaar HJ, Ong GL, Tan HS, Reubi JC 1988 Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinol (Copenh) 119:561-566
151. Siegel RA, Tolcsvai L, Rudin M 1988 Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). Cancer Res 48:4651-4655
152. Lamberts SW, Reubi JC, Uiterlinden P, Zuiderwijk J, van den Werff P, van Hal P 1986 Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology 118:2188-2194
153. Klijn JGM, Setyono-Han B, Bakker GH 1988 Prophylactic neuropeptide-analog treatment of a transplantable pancreatic tumor in rats. Prog Cancer Res Ther 35:350
154. Koper JW, Hofland LJ, van Koetsveld PM, den Holder F, Lamberts SW 1990 Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. Cancer Res 50:6238-6242
155. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV 1994 Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrinreleasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer 57:574-580
156. Froidevaux S, Hintermann E, Torok M, Macke HR, Beglinger C, Eberle AN 1999 Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 59:3652-3657
157. Mahy N, Woolkalis M, Manning D, Reisine T 1988 Characteristics of somatostatin desensitization in the pituitary tumor cell line AtT-20. J Pharmacol Exp Ther 247:390-396
158. Srikant CB, Heisler S 1985 Relationship between receptor binding and biopotency of somatostatin-14 and somatostatin-28 in mouse pituitary tumor cells. Endocrinology 117:271-278
159. Presky DH, Schonbrunn A 1988 Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 263:714-721
160. Bruno JF, Xu Y, Berelowitz M 1994 Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells. Biochem Biophys Res Commun 202:1738-1743
161. Vanetti M, Vogt G, Hollt V 1993 The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization. FEBS Lett 331:260-266
162. Rens-Domiano S, Law SF, Yamada Y, Seino S, Bell GI, Reisine T 1992 Pharmacological properties of two cloned somatostatin receptors. Mol Pharmacol 42:28-34
163. Schonbrunn A 1982 Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110:1147-1154
164. Xu Y, Berelowitz M, Bruno JF 1995 Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology 136:5070-5075
165. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, Muller OA 1994 Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 130:125-131
166. Visser-Wisselaar HA, Van Uffelen CJ, Van Koetsveld PM, Lichtenauer-Kaligis EG, Waaijers AM, Uitterlinden P, Mooy DM, Lamberts SW, Hofland LJ 1997 17-β-Estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology 138:1180-1189
167. Kimura N, Hayafuji C, Konagaya H, Takahashi K 1986 17β-Estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 119:1028-1036
168. Kimura N, Hayafuji C 1989 Characterization of 17-β-estradiol-dependent and -independent somatostatin receptor subtypes in rat anterior pituitary. J Biol Chem 264:7033-7040
169. Kimura N, Tomizawa S, Arai KN 1998 Chronic treatment with estrogen up-regulates expression of sst2 messenger ribonucleic acid (mRNA) but down-regulates expression of sst5 mRNA in rat pituitaries. Endocrinology 139:1573-1580
170. Xu Y, Song J, Berelowitz M, Bruno JF 1996 Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 137:5634-5640
171. Xu Y, Berelowitz M, Bruno JF 1998 Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Mol Cell Endocrinol 139:71-77
172. Kimura N, Tomizawa S, Arai KN, Osamura RY 2001 Characterization of 5′-flanking region of rat somatostatin receptor sst2 gene: transcriptional regulatory elements and activation by Pitx1 and estrogen. Endocrinology 142:1427-1441
173. Viguerie N, Esteve JP, Susini C, Logsdon CD, Vaysse N, Ribet A 1987 Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells. Biochem Biophys Res Commun 147:942-948
174. James RA, Sarapura VD, Bruns C, Raulf F, Dowding JM, Gordon DF, Wood WM, Ridgway EC 1997 Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor. Endocrinology 138:719-724
175. Candi E, Melino G, De Laurenzi V, Piacentini M, Guerrieri P, Spinedi A, Knight RA 1995 Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 96:141-145
176. Reubi JC, Heitz PU, Landolt AM 1987 Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65:65-73
177. Reubi JC, Waser B, Foekens JA, Klijn JG, Lamberts SW, Laissue J 1990 Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 46:416-420
178. Zhang CY, Yokogoshi Y, Yoshimoto K, Fujinaka Y, Matsumoto K, Saito S 1995 Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 210:805-815
179. Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM, Spada A 2001 Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 31:208-214
180. Petersenn S, Heyens M, Ludecke DK, Beil FU, Schulte HM 2000 Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clin Endocrinol (Oxf) 52:35-42
181. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A 2001 Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86:3809-3814
182. Abel F, Ejeskar K, Kogner P, Martinsson T 1999 Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer 81:1402-1409
183. Kwekkeboom DJ, Assies J, Hofland LJ, Reubi JC, Lamberts SW, Krenning EP 1993 A case of antibody formation against octreotide visualized with 111In-octreotide scintigraphy. Clin Endocrinol (Oxf) 39:239-243; discussion 244
184. Orskov H, Christensen SE, Weeke J, Kaal A, Harris AG 1991 Effects of antibodies against octreotide in two patients with acromegaly. Clin Endocrinol (Oxf) 34:395-398
185. Kendall-Taylor P, Chatterjee S, White MC, Harris MM, Davidson K, Besser GM, Wass JA 1989 Octreotide. Lancet 2:859-860 (Letter, Comment)
186. Milligan G 1996 Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Baillieres Clin Endocrinol Metab 10:177-187
187. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A 1999 Impact of gsp oncogene on the expression of genes coding for Gsα, Pit-1, Gi2α, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759-2765
188. Luthin DR, Eppler CM, Linden J 1993 Identification and quantification of Gi-type GTP-binding proteins that copurify with a pituitary somatostatin receptor. J Biol Chem 268:5990-5996
189. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR, McCormick F 1990 Two G protein oncogenes in human endocrine tumors. Science 249:655-659
190. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P 2001 Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145
191. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
192. Lamberts SW, Verleun T, Zuiderwijk JM, Oosterom R 1987 The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion. Acta Endocrinol (Copenh) 115:196-202
193. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552
194. Patel YC, Srikant CB 1994 Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135:2814-2817
195. Schaer JC, Waser B, Mengod G, Reubi JC 1997 Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70:530-537
196. Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, Mignon M, Lewin MJ 1997 Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 27:639-644
197. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann H 1998 Growth factor receptor expression in human gastroentero-pancreatic neuroendocrine tumours. Eur J Clin Invest 28:1038-1049
198. Mato E, Matias-Guiu X, Chico A, Webb SM, Cabezas R, Berna L, De Leiva A 1998 Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab 83:2417-2420
199. Laws SA, Gough AC, Evans AA, Bains MA, Primrose JN 1997 Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer 75:360-366
200. Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H 1998 Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77:632-637
201. Evans AA, Crook T, Laws SA, Gough AC, Royle GT, Primrose JN 1997 Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 75:798-803
202. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC 1998 Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620-627